Purchase Short-Term Access
Telmisartan did not reduce a composite of CV death, MI, HF, or stroke in high-risk patients intolerant to ACE inhibitors
Robin J. Taylor, MD
Annals of Internal Medicine 2009;150:JC2-6.
doi:10.7326/0003-4819-150-4-200902170-02006
Purchase Online access to this article for 24 hours
